www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

English 中文網(wǎng) 漫畫網(wǎng) 愛新聞iNews 翻譯論壇
中國網(wǎng)站品牌欄目(頻道)
當(dāng)前位置: Language Tips > Normal Speed News VOA常速

New studies on HIV treatment as prevention

[ 2012-04-26 15:49]     字號 [] [] []  
免費訂閱30天China Daily雙語新聞手機(jī)報:移動用戶編輯短信CD至106580009009

New studies on HIV treatment as prevention

Recent studies have shown that antiretroviral drugs can be used not only to treat HIV, but also to prevent infection in the first place. It's called pre-exposure prophylaxis or PrEP for short. Now, the western US state of California is launching new studies to determine PrEP's effectiveness beyond clinical trials and out in the real world.

Treatment as prevention has been shown to be highly successful in clinical trials. But will it work for people in high risk groups as they go about their daily lives? Will they adhere to the drug regimen even if it's taking only one pill a day?

These are some of the questions the California HIV/AIDS Research Program hopes to answer with three new studies. Mitchell Warren, head of the AIDS advocacy group AVAC, said these are "demonstration studies."

"These are not randomized controlled trials where we're telling people you may get placebo, you may get the active drug. And even if you get the active drug we don't know if it works. These are studies that are going to work with people in communities in California. People who are at risk. [They] are going to be explained that we think this product works based on these clinical trials, but only if you use [it]. And provide it to a small number of people to really better understand the safety and effectiveness in areas outside of clinical trials," he said.

MSM & transgenders

The studies focus on groups where HIV infections are rising rapidly.

Warren said, "All of these activities in California are focused on men who have sex with men and transgender women. And that is entirely understandable and appropriate given the epidemic in the United States. That is the leading area of need. At the same time we really hope as advocates that these demonstration projects in California are the first of many and that many more will look at other populations."

Those taking part in the study are being asked to follow what would appear to be a very simple drug regimen.

"It is a daily dose and it is a combined drug. It's a single pill, but with both active tenofovir and emtricitabine. And it is the same dose that is provided to people who are infected with HIV, who use the same pill for treatment. So the recommendation that was studied in the trial was the same single pill every day," he said.

Daily dose

However, Warren said pre-exposure prophylaxis is only effective if people take the pill. So the studies will also examine why people may skip doses, even if they only have to swallow one pill a day.

"People who took this pill consistently had high levels, an excess of 70 percent reduction of risk. People who didn't take the pill consistently didn't get any benefit at all. There was no added protection," he said.

When antitrovirals first came on the scene in the early and mid-1990s, people had to take dozens of pills a day. They had to take them at very specific times, sometimes with food, sometimes without. They often had very bad side effects, including nausea. There were even conditions called "buffalo hump" and "Crix belly," where body fat would build up behind the neck or on the abdomen. So, while lives were being saved, treatment could make people feel pretty sick.

Warren said it's much different today.

"We also have to remember the incredible scientific advances – from the 80s when getting HIV inevitably meant a very short life and a very painful disease in death – to a period of early antiretroviral therapy where we had drugs that were very difficult to take and very toxic, but they could save your life if you could withstand that – to a point now where people can take one or two pills a day. Much safer, much less toxic. We're in a very different place," he said.

In May, the US Food and Drug Administration will review the PrEP research. It could lead to greater access to prevention as treatment and provide accurate information to healthcare providers, insurance companies and potential users.

placebo: a substance containing no medication and prescribed or given to reinforce a patient's expectation to get well 安慰劑

Related stories:

Better treatment for HIV-positive pregnant women

Much progress, much to do on HIV

New guidelines would help ensure HIV treatment

Hepatitis C kills more Americans than HIV/AIDS

(來源:VOA 編輯:旭燕)

 
中國日報網(wǎng)英語點津版權(quán)說明:凡注明來源為“中國日報網(wǎng)英語點津:XXX(署名)”的原創(chuàng)作品,除與中國日報網(wǎng)簽署英語點津內(nèi)容授權(quán)協(xié)議的網(wǎng)站外,其他任何網(wǎng)站或單位未經(jīng)允許不得非法盜鏈、轉(zhuǎn)載和使用,違者必究。如需使用,請與010-84883631聯(lián)系;凡本網(wǎng)注明“來源:XXX(非英語點津)”的作品,均轉(zhuǎn)載自其它媒體,目的在于傳播更多信息,其他媒體如需轉(zhuǎn)載,請與稿件來源方聯(lián)系,如產(chǎn)生任何問題與本網(wǎng)無關(guān);本網(wǎng)所發(fā)布的歌曲、電影片段,版權(quán)歸原作者所有,僅供學(xué)習(xí)與研究,如果侵權(quán),請?zhí)峁┌鏅?quán)證明,以便盡快刪除。
 

關(guān)注和訂閱

人氣排行

翻譯服務(wù)

中國日報網(wǎng)翻譯工作室

我們提供:媒體、文化、財經(jīng)法律等專業(yè)領(lǐng)域的中英互譯服務(wù)
電話:010-84883468
郵件:translate@chinadaily.com.cn
 
 
主站蜘蛛池模板: 日本欧美亚洲 | 亚洲久久久久久久 | 92看片淫黄大片一级 | 久久国产精品影院 | 国产视频手机在线 | 失禁h啪肉尿出来高h男男 | 五月久久噜噜噜色影 | 亚洲国产欧美在线人成 | a级做爰片毛片视频 | 黄色成人在线网站 | 乱码一区 | 成人网18免费看 | 久久91精品国产91久久小草 | 久草在线观看首页 | 一区二区三区免费在线观看 | 亚洲男人第一天堂 | 日韩欧美在线视频观看 | 在线日韩欧美一区二区三区 | 午夜精品在线 | 精品一区二区三区在线播放 | 黄色三级视频 | 午夜无遮挡怕怕怕免费视频 | 久久久久久久国产精品 | 国产美女精品视频 | 手机看片自拍日韩日韩高清 | 九九国产精品视频 | 亚洲天堂美女 | 韩国一级a毛片 | 亚洲在线偷拍自拍 | 精品久久在线 | 欧美一区=区三区 | 神马午夜-午夜片 | 91中文字幕网 | 99在线免费观看视频 | 在线视频一区二区 | 在线综合+亚洲+欧美中文字幕 | 欧美一区视频 | 波多野结衣3女同在线观看 波多野结衣aⅴ在线 | 毛片视频网站在线观看 | 亚洲国产亚洲片在线观看播放 | 99视频久久精品久久 |